A Randomized Controlled Study to Compare Aprepitant (EMEND) to Standard Treatment as Prevention for Delayed Chemotherapy-induced Nausea and Vomiting (CINV) After Myeloablative Therapy for Patients With Lymphoproliferative Disease Undergoing Autologous Stem Cell Transplantation.

Trial Profile

A Randomized Controlled Study to Compare Aprepitant (EMEND) to Standard Treatment as Prevention for Delayed Chemotherapy-induced Nausea and Vomiting (CINV) After Myeloablative Therapy for Patients With Lymphoproliferative Disease Undergoing Autologous Stem Cell Transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone; Tropisetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jul 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 22 Jul 2010 Actual initiation date (May 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top